Articles

Poll

Podcasts

Slideshows

Videos

Psychiatry

Psychiatry condition center page is a comprehensive resource for clinical news and insights on mental illnesses. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for depression, schizophrenia, bipolar disorder, anxiety, and more.

A prospective cohort analysis of Denmark residents suggests correlation between cannabis overuse and risk of psychiatric conditions.

Cannabis Use Disorder Linked to High Bipolar Disorder, Depression Risk

The long-acting injectable can be administered once every 2 months to either treat schizophrenia or serve as a maintenance monotherapy for bipolar disorder.

FDA Approves Bi-Monthly Aripiprazole Injection for Schizophrenia, Bipolar Disorder

Children definite motor problems were more likely to have psychotic experiences compared to children with no definite motor problems.

Early Motor Impairment Could Forecast Schizophrenia, Bipolar Disorder

A new cross-sectional analysis suggest there are few options available for patients with schizophrenia or a serious mood disorder.

Smartphone Mental Health Apps Lack Diverse Features, Consistent Privacy Settings

There was a decrease in relapse observed for low-risk participants, but not high-risk individuals. 

Some Symptom Benefit for Bipolar Patients With Smartphone Program 

There remains a need for better treatments for bipolar disorder when it is identified early. 

Christopher Schneck, MD: Early Interventions for Bipolar Disorder

At Pri-Med West, primary care providers ask Dr. Michael Ziffra and Dr. Shirah Vollmer all the questions they have about treating mental illness and prescribing different classes of drugs. 

Psychiatrists Answer Questions on Depression, Bipolar Disorder in Primary Care Setting

Dr. Michael Ziffra talked during Pri-Med West 2022 about some of the challenges and gaps in research needed for better bipolar disorder care.


Michael Ziffra, MD: Screenings for Bipolar Disorder

The treatment represents the only FDA approved orally dissolving sublingual film for this patient population. 

FDA Approves Dexmedetomidine for Adults with Schizophrenia or Bipolar Disorder

Clinical decision support intervention resulted in a rate of change in total modifiable CV risk that was 4% lower among intervention patients compared to control. 

Clinical Decision Support Lowers CV Risk in Patients with Serious Mental Illness  

The HCPLive bipolar disorder page is a resource for medical news and expert insights on BPD. This page features expert-led coverage, articles, videos and research on the therapies and development of treatments for bipolar disease, and more.